TA-01

• Description:

  TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 acts as a cardiogenic inhibitor.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; Casein Kinase; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/TA-01.html

• Purity:

  99.86

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=C(F)C=CC=C4F)=N2

• Molecular Formula:

  C20H12F3N3

• Molecular Weight:

  351.32

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Laco F, et al. Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J Mol Cell Cardiol. 2015 Mar;80:56-70.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CK1; p38 MAPK

• CAS Number:

  [1784751-18-3]